AbbVie, Inc. CDR (CAD Hedged) (ABBV) Stock Price & Analysis

5 Followers

ABBV Stock Chart & Stats

CA$40.89CA$0.12(0.29%)

At close: Nov 11 4:00 PM EST

Day’s Range: CAD 40.73 - CAD 40.92
52-Week Range: CAD 26.89 - CAD 41.81
Previous Close: CAD 40.77
Volume: N/A
Average Volume (3M): 5,395
Market Cap: CAD 740.29B
Enterprise Value: CAD 164.06B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): 50.6
Beta: 0.28
Next Earnings: Feb 03, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: Jan 15, 2027
Dividend Yield: 2.34%

AbbVie, Inc. CDR (CAD Hedged) News

AbbVie’s Allergan Aesthetics announces results from Harmony In Diversity, Halo

Allergan Aesthetics, an AbbVie (ABBV) company, announced results from Harmony In Diversity and Halo, two Phase 4 studies of aesthetic treatment in adults on glucagon-like peptide-1 medications. Harmony In Diversity

4d agoABBV 4AB

AbbVie price target raised to $315 from $285 at Freedom Broker

Freedom Broker raised the firm’s price target on AbbVie (ABBV) to $315 from $285 and keeps a Buy rating on the shares following Q3 results, which the firm views “positively.”

1w agoABBV 4AB

AbbVie price target raised to $330 from $280 at RBC Capital

RBC Capital raised the firm’s price target on AbbVie (ABBV) to $330 from $280 and keeps an Outperform rating on the shares. The company’s quarterly results validate a durable growth

1w agoABBV 4AB

AbbVie price target raised to $325 from $279 at Leerink

Leerink analyst David Risinger raised the firm’s price target on AbbVie (ABBV) to $325 from $279 and keeps an Outperform rating on the shares. The firm notes the company’s commercial

1w agoABBV 4AB

AbbVie price target raised to $325 from $279 at Leerink

Leerink raised the firm’s price target on AbbVie (ABBV) to $325 from $279 and keeps an Outperform rating on the shares. The firm notes the company’s commercial portfolio is delivering

1w agoABBV 4AB

AbbVie signs global license agreement with Brise Pharmaceuticals in migraine

AbbVie (ABBV) provided an update on its exclusive license agreement with Brise Pharmaceuticals, which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsible for

1w agoABBV 4AB

AbbVie price target raised to $325 from $290 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on AbbVie (ABBV) to $325 from $290 and keeps an Overweight rating on the shares. AbbVie beat lowered Q3 expectations despite moderating Skyrizi

1w agoABBV 4AB

AbbVie price target raised to $322 from $288 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on AbbVie (ABBV) to $322 from $288 and keeps a Buy rating on the shares. Published first on TheFly – the

1w agoABBV 4AB

AbbVie price target raised to $338 from $290 at Canaccord

Canaccord raised the firm’s price target on AbbVie (ABBV) to $338 from $290 and keeps a Buy rating on the shares. The firm said Consistent solid performance in 3Q across

1w agoABBV 4AB

AbbVie price target raised to $295 from $260 at Citi

Citi analyst Geoff Meacham raised the firm’s price target on AbbVie (ABBV) to $295 from $260 and keeps a Neutral rating on the shares. The company reported another Skyrizi and

1w agoABBV 4AB

AbbVie: Solid Q3 Execution and Modest EPS Upside Prompt Hold Rating, Price Target Maintained at $294

Analyst Asad Haider from Goldman Sachs maintained a Hold rating on AbbVie and keeping the price target at $294.00. Asad Haider has given his Hold rating due to a combination

1w agoABBV 4AB

AbbVie Buy Rating Reaffirmed as Lutikizumab De-Risks HS Outlook; $310 Price Target Maintained

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie, with a price target of $310.00. Terence Flynn has given his Buy rating due

2w agoABBV 4AB

AbbVie: Hold Rating Maintained as Incremental Lutikizumab Data Support Neutral Stance; Price Target Reaffirmed at $275

AbbVie, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Yee from UBS maintained a Hold rating on the stock and has a $275.00 price

2w agoABBV 4AB

Analyst Reaffirms Buy Rating on AbbVie, Maintaining $280 Price Target After Strong CERVINO Phase III Data

Analyst Steve Scala of TD Cowen maintained a Buy rating on AbbVie, retaining the price target of $280.00. Steve Scala’s rating is based on the view that etentamig’s Phase III

1M agoABBV 4AB

ABBV FAQ

What was AbbVie, Inc. CDR (CAD Hedged)’s price range in the past 12 months?

AbbVie, Inc. CDR (CAD Hedged) lowest stock price was C$26.89 and its highest was C$41.81 in the past 12 months.

What is AbbVie, Inc. CDR (CAD Hedged)’s market cap?

AbbVie, Inc. CDR (CAD Hedged)’s market cap is C$740.29B.

When is AbbVie, Inc. CDR (CAD Hedged)’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were AbbVie, Inc. CDR (CAD Hedged)’s earnings last quarter?

AbbVie, Inc. CDR (CAD Hedged) released its earnings results on Oct 30, 2026. The company reported C$3.322 earnings per share for the quarter.

Is AbbVie, Inc. CDR (CAD Hedged) overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does AbbVie, Inc. CDR (CAD Hedged) pay dividends?

AbbVie, Inc. CDR (CAD Hedged) pays a dividend of C$0.251 which represents an annual dividend yield of 2.34%. See more information on AbbVie, Inc. CDR (CAD Hedged) dividends here

What is AbbVie, Inc. CDR (CAD Hedged)’s EPS estimate?

AbbVie, Inc. CDR (CAD Hedged)’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AbbVie, Inc. CDR (CAD Hedged) have?

AbbVie, Inc. CDR (CAD Hedged) has 1,767,616,300 shares outstanding.

What happened to AbbVie, Inc. CDR (CAD Hedged)’s price movement after its last earnings report?

AbbVie, Inc. CDR (CAD Hedged) reported an EPS of C$3.322 in its last earnings report. Following the earnings report the stock price went up 1.417%.

Which hedge fund is a major shareholder of AbbVie, Inc. CDR (CAD Hedged)?

Currently, no hedge funds are holding shares in TSE:ABBV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AbbVie, Inc. CDR (CAD Hedged)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

AbbVie, Inc. CDR (CAD Hedged) (ABBV) Earnings & Revenues

Historic Earnings Reports

ABBV Earnings Call

Q3 2026

Earnings Call SentimentPositive

The call was strongly positive. AbbVie reported double-digit revenue growth, exceeded earnings expectations, raised full-year revenue and EPS guidance, increased its dividend and highlighted broad momentum across immunology, neuroscience, oncology and its pipeline. The principal challenges were continued declines in Humira and Imbruvica, weakness in Juvéderm and the broader aesthetics category, acquired IPR&D expense, upcoming IRA pricing impacts and several pending regulatory or access milestones.

View all TSE:ABBV earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	16	5	1
Technical Analysis	4	5	1
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to TSE:ABBV
Company	Price & Change	Follow
TSE:NVSNovartis AG CAD Hedged CIBC CDR
TSE:PFEPfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S
TSE:JNJJohnson & Johnson Shs
TSE:MRKMerck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S
TSE:AMGNAmgen Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S

Compare TSE:ABBV Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

ABBV Stock Chart & Stats

AbbVie, Inc. CDR (CAD Hedged) News

AbbVie’s Allergan Aesthetics announces results from Harmony In Diversity, Halo

AbbVie price target raised to $315 from $285 at Freedom Broker

AbbVie price target raised to $330 from $280 at RBC Capital

AbbVie price target raised to $325 from $279 at Leerink

AbbVie price target raised to $325 from $279 at Leerink

AbbVie signs global license agreement with Brise Pharmaceuticals in migraine

AbbVie price target raised to $325 from $290 at Cantor Fitzgerald

AbbVie price target raised to $322 from $288 at Guggenheim

AbbVie price target raised to $338 from $290 at Canaccord

AbbVie price target raised to $295 from $260 at Citi

AbbVie: Solid Q3 Execution and Modest EPS Upside Prompt Hold Rating, Price Target Maintained at $294

AbbVie Buy Rating Reaffirmed as Lutikizumab De-Risks HS Outlook; $310 Price Target Maintained

AbbVie: Hold Rating Maintained as Incremental Lutikizumab Data Support Neutral Stance; Price Target Reaffirmed at $275

Analyst Reaffirms Buy Rating on AbbVie, Maintaining $280 Price Target After Strong CERVINO Phase III Data

ABBV FAQ

Company Description

AbbVie, Inc. CDR (CAD Hedged)

AbbVie, Inc. CDR (CAD Hedged) (ABBV) Earnings & Revenues

ABBV Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive